BioWorld

Feb. 6, 2004

View Archived Issues

XenoPort's Prodrug Efforts Yield $37M Equity Round

Biogen Idec, Celltech Team Up On CD40 Ligand Drugs

Nuvelo Adds Dendreon's Heart Product To Thickening Pipeline

Correction

Anika Wins Orthovisc Approval After Long Development Road

Other News To Note

Renovis Prices $66M IPO; SGI, Exact Pull In Follow-On Funds

Renovis Inc. entered the public arena as the third biotech company to conduct an initial public offering this year, raising $66 million. (BioWorld Today) Read More

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...